Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing study of group A and C meningococcal polysaccharide conjugate vaccine in infants
ChiCTR2100042656Phase 4Recruiting
- Sponsor
- Shanxi Center for Disease Control and Prevention
- Start
- Jul 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Group A and C Meningococcal Polysaccharide Conjugate Vaccine in meningococcal disease (2 arms), sponsored by Shanxi Center for Disease Control and Prevention. Primary endpoints: Serum bactericidal antibody titers and Antibody titers against diphtheria toxoid, tetanus toxoid, pertussis toxoid, and filamentous hemagglutinin. Started Jul 2020; status: recruiting.
02
Drugs
Group A and C Meningococcal Polysaccharide Conjugate Vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on ChiCTR2100042656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042656.